ReviewIntegrative medicine research2026
Chinese herbal medicine Ding Kun Dan for menopausal syndrome: A systematic review and meta-analysis of randomized controlled trials.
Review in Integrative medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical evidence on integrated Chinese-Western medicine for perimenopausal syndrome.Integrative medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Menopausal syndrome is a common condition in women during menopause, characterized by hormonal imbalances and various symptoms that negatively impact quality of life. Ding Kun Dan (DKD), a traditional Chinese herbal medicine, has been used to alleviate these symptoms, but its clinical efficacy and safety require further evaluation. Methods: A systematic search of eight databases was conducted through March 15, 2025. Randomized controlled trials (RCTs) were included if DKD was used alone or with conventional Western treatments. The primary outcome was the Kupperman Index; secondary outcomes included the Pittsburgh Sleep Quality Index, SF-36, Self-Rating Anxiety Scale, Self-Rating Depression Scale, estradiol, follicle-stimulating hormone, luteinizing hormone, and adverse events. Meta-analysis was performed using RevMan 5.4.1 and Stata 17. Results: A total of 21 RCTs involving 1981 participants were included. DKD combined with menopause hormone therapy (MHT) demonstrated superior efficacy in improving overall symptoms, sleep quality, quality of life, and reducing anxiety and depression, with a positive impact on hormone levels and fewer adverse events. DKD alone also showed comparable effects to MHT in improving symptoms and hormone levels. Additionally, DKD combined with oryzanol positively impacted hormone levels. Conclusions: DKD, both alone and in combination with MHT or oryzanol, demonstrates potential therapeutic effects for managing menopausal symptoms, but due to the low quality of included studies, results should be interpreted cautiously. Larger, high-quality RCTs are needed to confirm these findings. Protocol registration: PROSPERO, CRD42024621022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.